EP3937912A4 - Formulations de nanoparticules solides stabilisées de cannabinoïdes et d'analogues de cannabinoïdes à mûrissement d'ostwald réduit pour l'administration de médicaments par voie orale, inhalation, nasale et parentérale - Google Patents

Formulations de nanoparticules solides stabilisées de cannabinoïdes et d'analogues de cannabinoïdes à mûrissement d'ostwald réduit pour l'administration de médicaments par voie orale, inhalation, nasale et parentérale Download PDF

Info

Publication number
EP3937912A4
EP3937912A4 EP20770054.3A EP20770054A EP3937912A4 EP 3937912 A4 EP3937912 A4 EP 3937912A4 EP 20770054 A EP20770054 A EP 20770054A EP 3937912 A4 EP3937912 A4 EP 3937912A4
Authority
EP
European Patent Office
Prior art keywords
cannabinoids
inhalation
nasal
oral
drug delivery
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20770054.3A
Other languages
German (de)
English (en)
Other versions
EP3937912A1 (fr
Inventor
Ulagaraj Selvaraj
David L. Woody
John H. BOATRIGHT
Dong WEN
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of EP3937912A1 publication Critical patent/EP3937912A1/fr
Publication of EP3937912A4 publication Critical patent/EP3937912A4/fr
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/5123—Organic compounds, e.g. fats, sugars
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5107—Excipients; Inactive ingredients
    • A61K9/513—Organic macromolecular compounds; Dendrimers
    • A61K9/5169—Proteins, e.g. albumin, gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51—Nanocapsules; Nanoparticles
    • A61K9/5192—Processes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Optics & Photonics (AREA)
  • Nanotechnology (AREA)
  • Biomedical Technology (AREA)
  • Physics & Mathematics (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
EP20770054.3A 2019-03-13 2020-03-13 Formulations de nanoparticules solides stabilisées de cannabinoïdes et d'analogues de cannabinoïdes à mûrissement d'ostwald réduit pour l'administration de médicaments par voie orale, inhalation, nasale et parentérale Pending EP3937912A4 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962818041P 2019-03-13 2019-03-13
PCT/US2020/022821 WO2020186246A1 (fr) 2019-03-13 2020-03-13 Formulations de nanoparticules solides stabilisées de cannabinoïdes et d'analogues de cannabinoïdes à mûrissement d'ostwald réduit pour l'administration de médicaments par voie orale, inhalation, nasale et parentérale

Publications (2)

Publication Number Publication Date
EP3937912A1 EP3937912A1 (fr) 2022-01-19
EP3937912A4 true EP3937912A4 (fr) 2022-12-21

Family

ID=72427082

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20770054.3A Pending EP3937912A4 (fr) 2019-03-13 2020-03-13 Formulations de nanoparticules solides stabilisées de cannabinoïdes et d'analogues de cannabinoïdes à mûrissement d'ostwald réduit pour l'administration de médicaments par voie orale, inhalation, nasale et parentérale

Country Status (2)

Country Link
EP (1) EP3937912A4 (fr)
WO (1) WO2020186246A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023027673A2 (fr) * 2021-08-24 2023-03-02 Hacettepe Universitesi Rektorluk Méthode d'obtention d'un système d'administration de médicament nanoparticulaire et système d'administration de médicament nanoparticulaire obtenu par cette méthode

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090238878A1 (en) * 2006-07-24 2009-09-24 Chandra Ulagaraj Singh Solid Nanoparticle Formulation of Water Insoluble Pharmaceutical Substances With Reduced Ostwald Ripening
EP2243495A1 (fr) * 2008-01-16 2010-10-27 Shenyang Pharmaceutical University Système d'administration de médicament, son procédé de préparation et d'utilisation
WO2013006729A2 (fr) * 2011-07-05 2013-01-10 Wet Inc. Procédés, compositions et agents de liaison de récepteur cannabinoïde

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5576016A (en) * 1993-05-18 1996-11-19 Pharmos Corporation Solid fat nanoemulsions as drug delivery vehicles
GB0302672D0 (en) * 2003-02-06 2003-03-12 Astrazeneca Ab Pharmaceutical formulations
WO2016144376A1 (fr) * 2015-03-10 2016-09-15 Nanosphere Health Sciences, Llc Compositions et méthodes à base de nanoparticules lipidiques en tant que support de cannabinoïdes sous des formes posologiques dosées avec précision
EP3582755A4 (fr) * 2017-02-15 2020-12-23 Molecular Infusions, LLC Préparations

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090238878A1 (en) * 2006-07-24 2009-09-24 Chandra Ulagaraj Singh Solid Nanoparticle Formulation of Water Insoluble Pharmaceutical Substances With Reduced Ostwald Ripening
EP2243495A1 (fr) * 2008-01-16 2010-10-27 Shenyang Pharmaceutical University Système d'administration de médicament, son procédé de préparation et d'utilisation
WO2013006729A2 (fr) * 2011-07-05 2013-01-10 Wet Inc. Procédés, compositions et agents de liaison de récepteur cannabinoïde

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LUEBBERT CHRISTIAN C. ET AL: "Nanoparticle size and production efficiency are affected by the presence of fatty acids during albumin nanoparticle fabrication", PLOS ONE, vol. 12, no. 12, 27 December 2017 (2017-12-27), pages e0189814, XP055979710, DOI: 10.1371/journal.pone.0189814 *
See also references of WO2020186246A1 *

Also Published As

Publication number Publication date
WO2020186246A1 (fr) 2020-09-17
EP3937912A1 (fr) 2022-01-19

Similar Documents

Publication Publication Date Title
MX2023001592A (es) Inhalador de polvo seco.
EP3914324A4 (fr) Systèmes électroniques de distribution de gouttelettes actionnés par la respiration dotés de capacités de mesure de doses, procédés de topographie d'inhalation et procédés d'utilisation associés
MX2020012810A (es) Formulación de nicotina.
PH12016502065B1 (en) A hinged capsule inhaler
EP4306157A3 (fr) Système de distribution d'aérosol
WO2015166350A3 (fr) Inhalateur de poudre de nicotine aromatisée
BR112015021619A2 (pt) artigo fumígeno incluindo um membro de distribuição de aroma
WO2009008001A3 (fr) Dispositif d'inhalation
MX2009010289A (es) Composiciones para administracion nasal.
WO2015168077A8 (fr) Respirateur facial filtrant ayant un emplacement de filtre facial optimisé
EP3941561A4 (fr) Système d'administration par voie nasale de médicament
TR201109804A2 (tr) Tek dozlu inhalasyon cihazı.
EP3937912A4 (fr) Formulations de nanoparticules solides stabilisées de cannabinoïdes et d'analogues de cannabinoïdes à mûrissement d'ostwald réduit pour l'administration de médicaments par voie orale, inhalation, nasale et parentérale
UY31257A1 (es) Inhalador para la administracion de un medicamento pulverulento
EP3956002A4 (fr) Inhalateur à pression positive pour l'administration d'un médicament inhalable et procédés d'utilisation
WO2014007770A3 (fr) Compositions d'inhalation comprenant un corticostéroïde et du sorbitol
WO2014007772A3 (fr) Compositions d'inhalation contenant du glucose anhydre
EA201590734A8 (ru) Вдыхаемые лекарственные средства
EP3962661A4 (fr) Dispositifs et méthodes d'administration de médicament nasal
EP2682098A3 (fr) Compositions d'inhalation
MX2018012581A (es) Dispositivo espaciador para un inhalador.
MX2017013950A (es) Polvos de zolmitriptán para suministro pulmonar.
AU2016376027A1 (en) Flavoured nicotine powder
EP4041208A4 (fr) Compositions de cannabinoïdes pour administration par inhalation
AU2009329522B9 (en) Mouthpiece for an inhaler

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20211013

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20221117

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/05 20060101ALI20221111BHEP

Ipc: A61K 9/10 20060101ALI20221111BHEP

Ipc: A61K 31/045 20060101ALI20221111BHEP

Ipc: A61K 31/015 20060101ALI20221111BHEP

Ipc: A61K 31/01 20060101ALI20221111BHEP

Ipc: A61K 9/51 20060101AFI20221111BHEP

REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0031010000

Ipc: A61K0009510000

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: GRANT OF PATENT IS INTENDED

RIC1 Information provided on ipc code assigned before grant

Ipc: A61K 31/05 20060101ALI20240208BHEP

Ipc: A61K 9/10 20060101ALI20240208BHEP

Ipc: A61K 31/045 20060101ALI20240208BHEP

Ipc: A61K 31/015 20060101ALI20240208BHEP

Ipc: A61K 31/01 20060101ALI20240208BHEP

Ipc: A61K 9/51 20060101AFI20240208BHEP

INTG Intention to grant announced

Effective date: 20240223